Acurx Pharmaceuticals (NASDAQ:ACXP) Receives “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Acurx Pharmaceuticals (NASDAQ:ACXP) in a research report report published on Tuesday morning,Benzinga reports. They currently have a $12.00 price objective on the stock.

Acurx Pharmaceuticals Stock Performance

Shares of NASDAQ:ACXP opened at $0.89 on Tuesday. The stock has a market capitalization of $14.98 million, a price-to-earnings ratio of -0.81 and a beta of -1.85. Acurx Pharmaceuticals has a 1-year low of $0.72 and a 1-year high of $5.28. The company has a 50 day moving average price of $1.63 and a 200 day moving average price of $1.99.

Acurx Pharmaceuticals (NASDAQ:ACXP) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.06. During the same period in the prior year, the business earned ($0.24) EPS. On average, sell-side analysts expect that Acurx Pharmaceuticals will post -0.89 EPS for the current fiscal year.

Hedge Funds Weigh In On Acurx Pharmaceuticals

An institutional investor recently raised its position in Acurx Pharmaceuticals stock. Prospect Financial Services LLC grew its position in Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) by 6.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 295,075 shares of the company’s stock after buying an additional 16,975 shares during the quarter. Prospect Financial Services LLC owned approximately 1.86% of Acurx Pharmaceuticals worth $561,000 at the end of the most recent quarter. 11.53% of the stock is owned by institutional investors.

Acurx Pharmaceuticals Company Profile

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.